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40 Data from three completed cardiovascular outcome trials (CVOTs), EMPA-REG 
41 OUTCOME, CANVAS Program and DECLARE-TIMI 58, add to the evidence 
42 supporting the potential renoprotective effects of sodium-glucose linked transporter-2 
43 (SGLT2) inhibitors in patients with type-2 diabetes (T2D). Despite recommendations 
44 in recent guidelines, it is difficult to support a view that definitive evidence for 
45 renoprotection exists from these SGLT2 inhibitor CVOT results. To date, the only 
46 dedicated trial to report definitive data on the renal impact of SGLT2 inhibition is 
47 CREDENCE. Notably, the total number of patient relevant renal endpoint events 
48 (dialysis, transplant or renal death) observed in CREDENCE was significantly higher 
49 than the total for all three CVOTs collectively (183 events/4,401 patients vs. 69 
50 events/34,322 patients, respectively), which demonstrates the increased statistical 
51 power of CREDENCE for these renal endpoints. Treatment with canagliflozin was 
52 associated with a 30% relative risk reduction (RRR) in the primary composite 
53 endpoint of end-stage kidney disease, doubling of serum creatinine, or death from 
54 renal or cardiovascular causes and a 34% RRR for the renal-specific elements of this 
55 primary endpoint (P <0.001). Canagliflozin has therefore become the first US 
56 approved SGLT2 inhibitor to include an indication for renal risk reduction, in addition 
57 to T2D glycemic control and cardiovascular (CV) risk reduction. While confirmatory of 
58 the exploratory data from CVOTs, CREDENCE provides the first robust data on the 
59 effects of canagliflozin on patient relevant renal endpoints. Extrapolation to a 
60 conclusion of a SGLT2 inhibitor class effect cannot be made until additional renal 
61 trials with other SGLT2 inhibitors are reported.
62 Keywords: SGLT-2 inhibitors, CVOT, CKD, DKD, T2D, renoprotection, MARE
































































65 Given the controversy that certain anti-diabetic drugs, notably the thiazolidinedione 
66 rosiglitazone, might increase the risk of cardiovascular (CV) death, the US Food and 
67 Drug Administration (FDA) mandated for all new anti-diabetic drugs to undergo proof 
68 of cardiovascular (CV) safety through large-scale cardiovascular outcome trials 
69 (CVOTs).1,2 Since 2008, a number of CVOTs aimed at validating cardiovascular 
70 safety using the FDA specified major adverse cardiology events (MACE: a composite 
71 of cardiovascular death, nonfatal heart attackmyocardial infarction, and nonfatal 
72 stroke) as the primary endpoint have been performed.2 The EMPA-REG OUTCOME 
73 study published in 2015 was the first completed CVOT with a sodium-glucose linked 
74 transporter-2 (SGLT2) inhibitor.3 The study unexpectedly showed that a glucose-
75 lowering agent, empagliflozin, could reduce 3-point MACE, as well as cardiovascular 
76 mortality, hospitalisation for heart failure (HHF) and overall mortality when given in 
77 addition to standard care in T2D patients at high CV risk.3 CVOTs with other SGLT2 
78 inhibitors have also been completed and in keeping with the promising results from 
79 the EMPA-REG OUTCOME study also show reduction of CV events, particularly 
80 HHF.4,5 
81 Besides the surprising cardioprotective benefits of empagliflozin, a beneficial effect 
82 was also discovered from analysis of the secondary composite microvascular 
83 outcome, which was driven entirely by its renal component with respect to mitigating 
84 albuminuria and slowing deterioration of kidney function.6 This potential 
85 renoprotective effect created much excitement within the scientific community, and 
86 consequently, the renal microvascular component of the secondary outcome was 
87 further explored in a post-hoc sensitivity analysis.6 Secondary or exploratory 
88 analyses of major adverse renal events (MARE) renal outcomes for other SGLT2 































































89 inhibitors in CVOTs have also been completed or are ongoing, providing valuable 
90 insights into the potential of this drug class to offer renoprotection.7,8 
91 This review provides a critical reappraisal of the various renal outcomes reported 
92 from CVOTs to date. Whilst the CVOT secondary analyses prompted interesting 
93 hypotheses about the effect of SGLT2 inhibitors on renal outcomes in T2D patients, 
94 conclusive evidence required trials based on patient relevant renal endpoints, such 
95 as progression to end stage renal disease (ESRD) or death due to renal causes,9 
96 requiring studies in T2D patients with more advanced baseline kidney disease.
97 Of note, in all the SGLT2 inhibitor trials reporting renal outcomesMARE, none 
98 required either a biopsy or stringent exclusion of other potential causes of kidney 
99 disease. In the absence of clinical features suggestive of other aetiologies, there is a 
100 presumption that the underlying kidney disease is diabetic nephropathy but because 
101 other causes of chronic kidney disease (CKD) cannot be ruled out conclusively, 
102 diabetic kidney disease (DKD) is the term used in this review; this approach also 
103 mirrors current clincial practice. In addition, the first dedicated trial based on patient 
104 relevant renal endpoints, CREDENCE, has recently been published and is also 
105 discussed herein.
106 General limitations of SGLT2 inhibitor CVOTs
107 The CV safety of empagliflozin, canagliflozin and dapagliflozin has been evaluated in 
108 three large, placebo-controlled CVOTs, respectively named EMPA-REG OUTCOME, 
109 CANVAS Program and DECLARE-TIMI 58.3-5 The CANVAS Program consisted of an 
110 integrated analysis of two double-blind, randomised trials (CANVAS and CANVAS-R) 
111 that assessed canagliflozin versus placebo in participants with T2D who were at high 
112 risk of cardiovascular events. Another CVOT, VERTIS-CV, evaluating the SGLT2 































































113 inhibitor ertugliflozin has recently been completed but results had not yet been 
114 published at the time of this review.10 To date, the four completed CVOTs have 
115 enrolled 42,322 patients with T2D. All four CVOTs are multicentre, multinational 
116 studies and are described in detail elsewhere.3-6,10-12
117 Whilst these trials all had the common aim of reporting cardiovascular benefits 
118 associated with SGLT2 inhibition, it should be noted that there were potentially 
119 important differences in study design between them (Table 1). Due to the differences 
120 in study design and baseline characteristics of the study populations, reported trial 
121 outcomes cannot be extrapolated to the general T2D patient population.13 This is 
122 exemplified by the fact that only 1% of the US adult T2D population would have met 
123 the eligibility criteria for all four CVOTs.14
124 In addition to CV endpoints, renal endpoints, including the impact on albuminuria and 
125 renal function, were included only as secondary or exploratory outcomes in all trials 
126 (Table 1). Therefore, renal outcomes with SGLT2 inhibitors needed to be confirmed 
127 in trials specifically powered to assess patient relevant renal endpoints, as in the 
128 case of canagliflozin in the CREDENCE trial.11
129 Given the new evidence derived from CREDENCE and the CVOTs, the 2018 
130 American Diabetes Association (ADA) and the European Association for the Study of 
131 Diabetes (EASD) guidelines recommend that patients with T2D and clinical 
132 cardiovascular disease (CVD) with inadequate glucose control despite treatment with 
133 metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist.15 More 
134 recently, in the 2019 European Society of Cardiology (ESC) and the EASD 
135 guidelines, SGLT2 inhibitors are recommended as first-line treatment, before 
136 metformin in T2D patients who are at very high/high CV risk: (1) to lower glucose; (2) 
137 to reduce risk of death (empagliflozin only) in patients with CVD; (3) to lower risk of 































































138 HF hospitalisation; and (4) to reduce progression of DKD.16 However, the use of 
139 SGLT2 inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists as 
140 monotherapy remains off-label in most countries since there are no studies to date 
141 on the use of these compounds as monotherapy in any CVOT. In most of the SGLT2 
142 inhibitor CVOTs, metformin was used as background therapy in 74-82% of patients 
143 and CV outcomes in patients with and without metformin therapy were quite different 
144 when the subgroup analyses data were reported.3-5
145 Baseline renal risk of study participants in SGLT2 inhibitor CVOTs
146 Figure 1 shows the very different baseline renal risk of patients included in the 
147 DECLARE-TIMI 58, EMPA-REG OUTCOME, CANVAS Program and CREDENCE 
148 studies. Since the primary aim of the CVOTs was assessment of CV safety, and 
149 although some of patients in the analysis populations of the three completed SGLT2 
150 inhibitor trials showed prevalent kidney disease at baseline (e.g. 32% of patients in 
151 the EMPA-REG OUTCOME trial had prevalent DKD), overall the CVOTs populations 
152 did not match the high renal risk of patients in CREDENCE nor the high degree of 
153 renal progression required for inclusion of patients in the landmark RENAAL 
154 (Angiotensin II Antagonist Losartan) study and the Irbesartan Diabetic Nephropathy 
155 Trial (IDNT).17 Differences in design, study populations and renal outcomes among 
156 the three reported CVOTs prevent reliable comparison of between-study outcomes. 
157 In EMPA-REG OUTCOME, potential study participants were excluded with an eGFR 
158 < 30 ml/min/1.73m2 but there was were no exclusion criteria for albuminuria or other 
159 aetiologies of kidney disease.3 In addition, subjects were not required to be on a 
160 maximum tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or 
161 angiotensin-II receptor blocker (ARB), currently the primary treatment for the 































































162 prevention and treatment of DKD; however, nearly all participants at baseline were 
163 reported to be taking a renin-angiotensin-aldosterone system (RAAS) blocker 
164 (notably, 80.7% were on an ACE inhibitor or ARB as part of standard-of-care).3
165 Of the 7,020 participants enrolled in EMPA-REG, there were 5,199 patients with an 
166 eGFR of  60mL/min/1.73 m2,3,6 of which 64% had normoalbuminuria (UACR < 30 
167 mg/g), 27% had microalbuminuria and 8% had macroalbuminuria; two participants 
168 had missing data for eGFR.6 There were 1,819 patients with an eGFR < 
169 60mL/min/1.73 m2, 3 of which 47% had normoalbuminuria, 34% had 
170 microalbuminuria and 18% had macroalbuminuria.6 
171 Like EMPA-REG OUTCOME, subjects for both CANVAS and CANVAS-R were not 
172 required to be on a maximum tolerated dose of an ACE inhibitor or ARB, although 
173 nearly all were reported to be on a RAAS blocker at baseline (80.2%).4 Of the 10,142 
174 participants recruited, there were 8,101 patients with an eGFR of  60mL/min/1.73 
175 m2 at baseline, of which 73% had normoalbuminuria.18 Notably, 2,039 (20.1%) of 
176 participants had an eGFR < 60mL/min/1.73 m2 at baseline, of which 55% had 
177 normoalbuminuria.18
178 The DECLARE-TIMI 58 population was at lower risk of adverse renal 
179 outcomesMARE than EMPA-REG OUTCOME and CANVAS Program populations 
180 (Figure 1; Table 1), which themselves had overall lower renal risk populations 
181 compared with the landmark ARB trials, RENAAL and IDNT. The study population in 
182 DECLARE-TIMI 58 did not have substantially reduced eGFR at baseline (mean 
183 eGFR was 85.2 ml/min/1.73 m2) because patients with creatinine clearance < 
184 60mL/min/1.73 m2 were excluded. Most participants had preserved renal function at 
185 baseline and notably, 69.1% had normoalbuminuria, i.e. only 30% had baseline 
186 DKD.5,7 Of the 17,160 participants enrolled, 15,894 (93%) had an eGFR of  60 































































187 mL/min/1·73 m2 and 1,265 (7%) had an eGFR of < 60 mL/min/1·73 m2 at baseline.7 
188 Similarly, the majority (approximately 85%) of study patients were taking an ACE 
189 inhibitor/ARB at baseline, however there was no specific directive to ensure optimal 
190 treatment.5
191 Renal endpoints and outcomes in SGLT2 inhibitor CVOTs
192 Although the CVOTs under consideration in this manuscript had MACE as the 
193 primary endpoint, the regulators asked different questions of the sponsors which 
194 affected the renal recruitment criteria. Overall, the main renal endpoint definitions in 
195 CVOTs prior to CREDENCE are heterogeneous making direct comparisons between 
196 trials difficult, and outcome measures were based on surrogate endpoints, such as 
197 creatinine doubling and progression of albuminuria (Table 2).3 Furthermore, renal 
198 composite endpoints were used to provide evidence of SGLT2 inhibitor efficacy in 
199 slowing the loss of renal function and delaying progression to ESRD.19
200 Efforts to identify optimal endpoints for evaluating DKD treatments, as well as efforts 
201 to standardise the reporting of the data, are important for expediting the development 
202 of new anti-diabetic treatments for DKD. For future trials, uniformly agreed definitions 
203 for renal endpoints would make meta-analyses easier and would facilitate the 
204 comparison of different studies.9 New major renal events (MARE) definitions have 
205 been developed, which include major morbidity and mortality events (e.g. 
206 development of new-onset DKD, reaching ESRD, starting RRT or receiving a kidney 
207 transplant, and mortality from renal cause).9 Results from future trials that adopt the 
208 use of MARE as a primary outcome and add intermediate endpoints and surrogate 
209 endpoints where appropriate would be more comparable and patient relevant.9 
210 Indeed CREDENCE, a post-hoc analysis of the composite endpoint of RRT, 































































211 transplantation or death was assessed with a view to providing patient relevant 
212 clinical trial data.8
213 Figure 2 shows the composite renal outcome rates and composite renal outcome 
214 relative risk reductions (RRRs) in CVOTs.
215 BOX 1 provides a summary of key issues with renal endpoints and outcomes 
216 pertaining to the design of EMPA-REG OUTCOME, CANVAS Program and 
217 DECLARE-TIMI 58 CVOTs.
218 EMPA-REG OUTCOME 
219 In analyses of the renal endpoints, it was concluded that empagliflozin improved 
220 renal outcomes defined by reduced risk of incident or worsening DKD, reduced 
221 progression to macroalbuminuria, reduced incidence of renal-replacement therapy 
222 and reduced occurrence of doubling of serum creatinine compared with placebo 
223 (Table 2; Box 1). 
224 It is however important to note that renal endpoints were redefined during the main 
225 EMPA-REG OUTCOME trial and that key aspects of the endpoints were either 
226 defined after trial completion (although reportedly before database lock) or were not 
227 defined prospectively.20 No renal related endpoints were included in plans to control 
228 the overall Type-1 error rate because, as the sponsor explicitly stated, the endpoints 
229 “are of exploratory nature and no correction for multiple hypothesis testing was 
230 made.”21 In the final protocol, the secondary safety outcome was a composite 
231 microvascular outcome that included the first occurrence of any of the following: the 
232 initiation of retinal photocoagulation, vitreous haemorrhage, diabetes-related 
233 blindness, or new or worsening DKD. The first renal microvascular outcome was 
234 incident or worsening DKD, defined as progression to macroalbuminuria (UACR > 































































235 300 mg/g), doubling of serum creatinine with an eGFR (MDRD) ≤ 45 mL/min/1.73m2, 
236 initiation of continuous renal replacement therapy, or death due to renal disease.3,6
237 EMPA-REG OUTCOME was not a dedicated renal outcomes trial and renal 
238 endpoints were not adjudicated during the study. However, the results for the 
239 composite renal outcomesMARE were validated in a post-hoc sensitivity analysis in a 
240 subgroup analysis of patients with prevalent DKD at study entry defined as eGFR 
241 (Modification of Diet in Renal Disease (MDRD) Study equation) < 60 ml/min/1.73 m2 
242 and/or macroalbuminuria (UACR > 300mg/g) at baseline.6 The first renal outcome of 
243 this post-hoc subgroup study was a four-point composite of new onset or worsening 
244 of DKD (defined as progression to macroalbuminuria, doubling of serum creatinine 
245 level associated with an eGFR  45 mL/min/1.73 m2, initiation of RRT and renal 
246 death). A total of 6,185 patients entered this pre-specified subgroup analysis. The 
247 incident or worsening DKD endpoint occurred in 388 of 2061 (18.8%) placebo and 
248 525 of 4124 (12.7%) in empaglifozin treated patients which resulted in a relative risk 
249 reduction of 39% in patients that received empaglifozin (Hazard Ratio (HR): 0.61; 
250 95% CI: 0.53, 0.7; P <0.001).6 As defined, the new onset macroalbuminuria 
251 component could capture small, transient and/or reversible changes in albuminuria of 
252 uncertain clinical significance.21 In fact, there was no difference in albuminuria 
253 between the placebo and empagliflozin arms following discontinuation of study drug.  
254 It has been postulated that SGLT-2 inhibitors exert a haemodynamic effect rather 
255 than a direct effect on the underlying disease process, however the exact mechanism 
256 remains to be elucidated.22 In the recent randomised, double-blind RED trial, the 
257 renal haemodynamic effects of an SGLT-2 inhibitor were shown to be caused by 































































258 post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in 
259 metformin-treated T2D patients.23
260 In EMPA-REG OUTCOME, there was no significant between-group differences in the 
261 rate of incident albuminuria for patients with normoalbuminuria at baseline (51.5 and 
262 51.2% with empagliflozin and placebo, respectively; P =0.25).6 However, overall 
263 progression to macroalbuminuria was reduced by 38% (P <0.001), suggesting a 
264 different effect of the SGLT-2 inhibitor on patients with different levels of urinary 
265 albumin excretion.6 Efficacy claims of “sustained normo- or microalbuminuria in 
266 patients with baseline macroalbuminuria” are difficult to maintain.24 To date, 
267 regulatory agencies have not accepted on-treatment effects on albuminuria as a 
268 surrogate for clinical outcomes in diabetic nephropathy, in part because therapies 
269 can have acute and reversible pharmacologic effects on albuminuria that may differ 
270 from their long-term effects on the irreversible loss of renal function and underlying 
271 disease progression.25,26 It is also important to note that persons with a reduction in 
272 eGFR without elevations in urinary albumin may or may not show benefit from SGLT-
273 2 inhibitor treatment, however further trials will be required to determine this.
274 CANVAS Program
275 Analysis of renal endpoints showed that canagliflozin reduced the occurrence of 
276 progression to albuminuria and increased the occurrence of regression of 
277 albuminuria (Table 2; Box 1). A renal adjudication committee was responsible for 
278 adjudicating the following endpoint events: ESRD (i.e. need for RRT), doubling of 
279 serum creatinine and 40% reduction of eGFR.4 However, as with EMPA-REG 
280 OUTCOME, the CANVAS Program was not designed to formally examine renal 
281 outcomes and the total number of renal events was small. The decrease in HR for 































































282 composite renal outcome was driven primarily by the surrogate endpoints of renal 
283 function rather than patient relevant MARE namely, ESRD, renal transplantation or 
284 renal death.
285 Canagliflozin reduced the time to first occurrence of all adjudicated renal composite 
286 endpoints relative to placebo with the upper bound of the 95% CI excluding 1.0.4 The 
287 composite outcome of sustained 40% reduction in eGFR, renal death and RRT 
288 occurred less frequently in the canagliflozin group compared with the placebo group 
289 (5.54 vs. 9.03/1,000 patient-years, respectively) corresponding to a HR of 0.60 (95% 
290 CI: 0.47, 0.77).4 Furthermore, lower HRs were also observed in the canagliflozin 
291 group when progression to macroalbuminuria (HR: 0.57; 95% CI: 0.50, 0.66) or CV 
292 death (HR: 0.77; 95% CI: 0.66, 0.89) were included in this composite.4 
293 The CANVAS Investigators introduced alternative renal endpoints in their analyses, 
294 i.e. a 40% decline in eGFR and eGFR slope, which might be more practical in trials 
295 of shorter duration.4,27 However, since these endpoints are less applicable at higher 
296 baseline renal function (e.g. as typically the case in CVOTs), effects on these 
297 endpoints might not translate into true improvement in MARE. For each of these 
298 outcomes, substituting the 40% reduction in eGFR component with doubling of 
299 serum creatinine resulted in fewer events but similar canagliflozin treatment effect 
300 estimates.4 The results of the composite endpoints were mainly driven by sustained 
301 40% reduction in eGFR and doubling of serum creatinine.4 
302 DECLARE-TIMI 58
303 In addition to the FDA-mandated primary safety endpoint (non-inferiority for 3-point 
304 MACE) and the primary efficacy endpoint superiority for 3-point MACE, a new co-
305 primary composite efficacy endpoint of HHF and CV death was added, due to new 































































306 insights from previously reported SGLT2 inhibitor CVOTs.5 However, because the 
307 study failed to meet the primary efficacy endpoint of superiority for 3-point MACE, the 
308 pre-specified adjudicated secondary cardio-renal composite outcome defaulted to an 
309 exploratory endpoint. This cardio-renal exploratory endpoint was defined as a 
310 sustained decline of at least 40% in estimated eGFR to < 60 mL/min/1·73m², ESRD 
311 (defined as dialysis for  90 days, kidney transplantation, or confirmed sustained 
312 eGFR < 15mL/min/1·73 m²), or death from renal or cardiovascular causes.5 A 
313 second, renal-specific composite outcome was the same but excluded death from CV 
314 causes and this occurred in 1.5% versus 2.8% of patients in the dapagliflozin and 
315 placebo treatment groups, respectively (HR 0.53; 95% CI: 0.43-0.66).5 Hence, the 
316 exploratory outcome analysis showed a 47% RRR with dapagliflozin in the composite 
317 renal outcome.5 Despite the good HR reported for the renal composite endpoint, it 
318 was mainly driven by a reduction in doubling of serum creatinine.7 
319 Overall, the authors from DECLARE-TIMI 58 concluded that dapagliflozin was able to 
320 prevent renal function deterioration and clinically important renal endpoints compared 
321 with placebo in T2D patients with and without established atherosclerotic CVD and 
322 preserved renal function.5 Based on the Phase 3 DECLARE-TIMI 58 trial results, the 
323 European Commission has recently approved a label update for dapagliflozin to 
324 include both CV and renal data. However, owing to the fact that this trial included a 
325 population with near normal renal function at baseline (93% eGFR > 
326 60mL/min/1.73m2), only a small number of renal events was actually reported (Table 
327 1; Box 1).5 Of the 17,160 patients enrolled in this study, only 11 vs. 27 ESRD or 
328 renal death events were reported for the dapagliflozin and placebo groups, 
329 respectively (HR: 0.41; P =0.012).7 The inclusion of sustained eGFR changes only 































































330 (i.e. with two consecutive tests ≥ 30 days apart) was an important parameter in the 
331 renal endpoint definition.
332 Supporting the DECLARE-TIMI 58 cardio-renal outcomes, results from a pre-
333 specified sub-analysis, recently presented at the 2019 ESC conference, showed that 
334 dapagliflozin's effect on CV death/HHF and MACE was consistent across baseline 
335 renal function and albuminuria status (P =0.29 for CV death/HHF and P =0.62 for 3-
336 point MACE), 28 although numerically greatest (42% RRR) in patients with reduced 
337 eGFR and albuminuria.28 Similarly in a recent meta-analysis which included EMPA-
338 REG OUTCOME, CANVAS Program, DECLARE-TIMI 58 and CREDENCE data, 
339 renoprotection was consistent irrespective of baseline albuminuria (Ptrend = 0.66) with 
340 benefit identified at all levels of kidney function, including for patients with a baseline 
341 eGFR 30-40 mL/min/1.73m2 (Relative Risk 0.70: 95% CI 0.54-0.91; P =0.008).29 
342 Despite the results of this meta-analysis being driven predominantly by canagliflozin 
343 in the single CREDENCE study, renoprotection with the other SGLT2 inhibitors, 
344 empagliflozin and dapagliflozin, seems consistent.29
345 Renal endpoints and outcomes in CREDENCE
346 As previously mentioned, CREDENCE is the first and only completed clinical trial to 
347 investigate a SGLT2 inhibitor primarily for renal protection in patients with T2DM and 
348 CKD.12 Baseline eGFR and UACR for CREDENCE was 56.2 mL/min/1.73 m2 and 
349 927 mg/g, respectively.12 Figure 2 shows the composite renal outcome rates and 
350 composite renal outcome relative risk reductions (RRRs) in CREDENCE versus the 
351 SGLT2 inhibitor CVOTs.
352 CREDENCE included 4,400 patients and was stopped early due to a signal of clear 
353 efficacy in the prevention of the composite renal and cardiovascular primary 































































354 endpoint, 12 doubling of serum creatinine, ESRD, renal death and CV death; both 
355 ESRD and renal death were robustly defined. In addition, unlike the SGLT2 inhibitor 
356 CVOTs, all renal endpoints were assessed by a blinded adjudication committee.12 
357 The relative risk of the primary outcome was 30% lower for patients taking 100mg of 
358 canagliflozin (a dose that had no effect upon lowering of HbA1C) compared with 
359 placebo (HR: 0.70; 95% CI: 0.59, 0.82; P =0.00001).12,16 There was also 34% RRR 
360 for the renal-specific elements of the primary endpoint, excluding CV death, for those 
361 taking canagliflozin (HR: 0.66; 95% CI: 0.53, 0.81; P <0.001) (Table 2).12 By 42 
362 months, eGFR had dropped by a mean of -1.85 mg/mL/min/1.73m2 per year in the 
363 canagliflozin group and a mean of -4.59 mg/mL/min/1.73m2 per year in the placebo 
364 group, which translates to a 60% reduction in eGFR slope decline.8
365 The renal results observed in the overall study population were consistent across the 
366 primary and secondary prevention groups, across all 15 subgroups tested, 
367 regardless of prior CVD history. Specifically, canagliflozin reduced the risk of ESRD 
368 by 32% (HR: 0.69; 95% CI: 0.51 to 0.95; P =0.89) and 33% (HR: 0.67; 95% CI: 0.47, 
369 0.96; P =0.89) in the primary (≥ 50 years of age with ≥ 2 risk factors for CV events 
370 but with no prior CV event) and the secondary (≥ 30 years of age with a prior CV 
371 event) prevention groups, respectively.30 The number needed to treat with 
372 canagliflozin was 22 to prevent one primary composite outcome event (doubling of 
373 serum creatinine, ESRD, renal death, or CV death) over 2.5 years.12 To prevent one 
374 primary composite outcome event over 2.5 years in patients with eGFR (> 30 to < 45 
375 ml/min/1.73m2) the number needed to treat with canagliflozin was 16.12,31
376 A signal of potential increased risk of distal fracture and lower limb amputation was 
377 noted in the CANVAS Program 12 but was not seen in CREDENCE or in a cohort 
378 study of 79,964 T2D patients.16,32































































379 Based on the exploratory/secondary renal endpoints of the CVOTs plus the 
380 dedicated CREDENCE trial, empagliflozin, canagliflozin or dapagliflozin are now 
381 recommended as treatment to reduce progression of DKD.16 CREDENCE also 
382 demonstrated that canagliflozin may be used with benefit down to an eGFR of 30 
383 mL/min/1.73m2.12,16 Hence the ESC/EASD 2019 guidelines state that “treatment with 
384 an SGLT2 inhibitor is associated with a lower risk of renal endpoints and should be 
385 considered for T2D patients if eGFR is 30 to < 90 mL/min/1.73 m2.”16 
386 Strength of evidence for renal outcome modification in T2DM with SGLT2 
387 inhibitors
388 Ideally, before adoption of the SGLT2 inhibitor CVOT results to support indications 
389 for renoprotection in guidelines, confirmatory results from other dedicated renal 
390 outcome trials in addition to CREDENCE are needed.33 Such studies must include 
391 patients that who are at substantially higher risk of renal events than those enrolled in 
392 the published CVOTs, to ensure that a sufficient number of sustained renal events is 
393 accrued, that there is appropriate follow-up, and that the study design uses the US 
394 Food and Drug Association (FDA)-approved and generally-accepted renal endpoints, 
395 appropriate measurements and adjudication.34 Notably, longer duration of follow-up 
396 (e.g., 3 years) in kidney trials many be more important for renal outcomes than 
397 cardiovascular outcomes.
398 Despite consistency of RRR for renal outcomesMARE across the SGLT2 inhibitor 
399 CVOTs (EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58), the 
400 rate of sustained renal events was extremely low at just 69 events per 34,322 
401 participants.29 In contrast, the total number of sustained RRT events from 
402 CREDENCE was 183 events per 4,401 participants (HR: 0.72; 95% CI: 0.54–0.97).12 































































403 Excluding CREDENCE data, the strength of evidence for renoprotection with SGLT2 
404 inhibitors in patients with CKD has also been assessed in a second recent systematic 
405 review and meta-analysis.35 The results for Renal outcomesMARE were found to be 
406 less robust than for CV outcomesMACE, due to the relatively small number of renal 
407 events.35 The systematic review states that the “effect on the renal composite 
408 outcome was no longer clear in a sensitivity analysis excluding the DECLARE-TIMI 
409 58 trial,” because most of the renal events used in the meta-analysis were from this 
410 trial.35 
411 Nevertheless, it is noteworthy that there were 765, 533, 1,184 and 758 persons with 
412 baseline macroalbuminuria in EMPA-REG OUTCOME, CANVAS Program, 
413 DECLARE-TIMI 58 and VERTIS-CV, respectively, for a total of 3240 persons, which 
414 is comparable to the 3,873 with macroalbuminuria in CREDENCE, although the 
415 prevalence of macroalbuminuria was lower in the CVOTs and eGFR was certainly 
416 lower in CREDENCE. 
417 Taken together it is clear that the renoprotective effects reported in the SGLT2 
418 inhibitor CVOTs are substantially less robust than those observed in CREDENCE. As 
419 highlighted in the recent ESC/EASD guidelines, whether the renoprotection 
420 demonstrated in CREDENCE is a SGLT2 inhibitor class effect or specific to 
421 canagliflozin remains to be determined by further additional trials with the other 
422 SGLT2 inhibitors in patients with more advanced CKD.16
423 Ongoing and future studies
424 Based on the results from the landmark CREDENCE renal outcomes trial, 
425 canagliflozin has recently been approved by the FDA to reduce the risk of (i) end-
426 stage kidney disease; (ii) worsening of kidney function; and (iii) cardiovascular 































































427 death/hospitalisation for heart failure in people with T2D and CKD. Canagliflozin is 
428 therefore the first SGLT2 inhibitor to include indications for T2D glycemic control, CV 
429 risk reduction and renal risk reduction.36 
430 Several trials are underway to further investigate the cardiovascular and renal 
431 benefits of the other SGLT2 inhibitors. The Study of Heart and Kidney Protection 
432 With Empagliflozin (EMPA-KIDNEY; NCT03594110), will evaluate approximately 
433 5,000 patients with established CKD, with and without T2DM, to determine the effect 
434 of empagliflozin on time to clinically relevant kidney disease progression or CV 
435 death.37 The findings of this trial will build on results of the EMPA-REG OUTCOME 
436 trial, with new data on the effects of empagliflozin in a broad range of people, with or 
437 without T2D.
438 The DAPA-CKD (Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes 
439 and Cardiovascular Mortality in Patients With Chronic Kidney Disease; 
440 NCT03036150), evaluating the effect of dapagliflozin on renal outcomes and 
441 cardiovascular mortality in patients with chronic kidney disease is already fully 
442 recruited with patients now under follow-up. The primary endpoint will be time to the 
443 first occurrence of any of the components of the composite: ≥50% sustained decline 
444 in eGFR or reaching ESRD, CV death or renal death.37
445 The recently completed VERTIS-CV CVOT (NCT01986881) is evaluating ertugliflozin 
446 in 8,238 patients with established atherosclerotic CVD and includes a secondary 
447 composite outcome of renal death, dialysis/transplant or doubling of baseline serum 
448 creatinine.10,37
449 Outcomes have recently been reported for the DAPA-HF trial (Study to Evaluate the 
450 Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular 
451 Death in Patients With Chronic Heart Failure; NCT03036124).38,39 DAPA-HF primarily 































































452 investigated the effect of dapagliflozin on a composite of worsening heart failure 
453 (hospitalisation or an urgent visit resulting in intravenous therapy for heart failure) or 
454 cardiovascular death in patients with chronic heart failure with reduced ejection 
455 fraction (HR: 0.74; 95% CI: 0.65, 0.85; P <0.001).39 A secondary outcome measure 
456 will include time to the first occurrence of any of the components of a renal composite 
457 (≥50% sustained decline in eGFR, ESRD, or renal death).37,38
458 Two Phase 3 trials are currently recruiting subjects to investigate the safety and 
459 efficacy of empagliflozin versus placebo added to guideline-directed therapy in 
460 patients with heart failure. The two EMPEROR (EMPagliflozin outcomE tRial in 
461 Patients With chrOnic heaRt Failure) trials will include patients with heart failure due 
462 to either reduced ejection fraction (EMPEROR-Reduced; NCT03057977) or with 
463 preserved ejection fraction (EMPEROR-Preserved; NCT03057951).37 Secondary 
464 endpoints in both trials will include change/slope in eGFR from baseline, and time to 
465 first occurrence of chronic dialysis or renal transplant and sustained reduction of 
466 eGFR.37 
467 Conclusions
468 Insights into the potential role of the SGLT2 inhibitor class of drugs in the prevention 
469 and treatment of DKD have been provided by CVOTs and CREDENCE.4,6,7,12 The 
470 overall renoprotective effect, although a secondary outcome in the CVOTs, does 
471 seem to be consistent for empagliflozin, canagliflozin and dapagliflozin with no 
472 evidence of heterogeneity.29 In a recent meta-analysis, SGLT2 inhibition reduced 
473 ESRD (0·65, 0·53–0·81, p<0·0001), and acute kidney injury (0·75, 0·66–0·85, 
474 p<0·0001), with consistent benefits across studies (EMPA-REG OUTCOME, 
475 CANVAS Program and CREDENCE, and DECLARE–TIMI 58).29 Irrespective of 































































476 baseline albuminuria and use of RAAS blockade, renoprotection was also consistent 
477 across the studies.29 However, concurrent with the latest 2019 ESC/ EASD 
478 guidelines, Neuen et al. (2019) highlighted that the consistency of RRR in renal 
479 outcomes being a class effect among the SGLT2 inhibitors remains uncertain 
480 because of the different characteristics of participants in the included SGLT2 inhibitor 
481 CVOTs as well as the fact that only the CREDENCE trial was specifically powered for 
482 renal outcomes.16,29
483 Thus, from the CVOT data alone, it would be inappropriate to conclude that SGLT2 
484 inhibitors provide a clear favourable effect on patient relevant clinical outcomes in 
485 DKD and also that any such effect would be a class effect.16 The only definitive 
486 prospective clinical trial that has demonstrated a clear, highly clinically significant 
487 effect on major renal outcomes in participants with CKD has been CREDENCE. Until 
488 the ongoing dedicated renal trials for empagliflozin and dapagliflozin report 
489 conclusions on the renoprotective efficacy of these compounds in DKD and on class 
490 effects cannot be made with complete confidence.
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509 Table 1. Key differences between the study design of SGLT2 inhibitor CVOTs and CREDENCE.
Trial Name EMPA-REG OUTCOME CANVAS Program DECLARE-TIMI 58 VERTIS-CV CREDENCE
Comparisons 1:1:1 ratio: empagliflozin 
10 mg, empagliflozin 25 
mg, placebo
CANVAS 1:1:1 ratio: 
canagliflozin 300 mg, 
canagliflozin 100 mg, 
placebo; CANVAS-R 1:1 
ratio: canagliflozin 100 mg 












Number of patients in primary analysis 7,020 10,142 17,160 8,238 4,401
Main inclusion criteria:
 CVD established CVD age  30 years and 
established CVD or age  
50 years with  2 CVD risk 
factors 






 Renal no criteria micro- or 
macroalbuminuria
no criteria no criteria stage 2 or 3 CKD 
or 
macroalbuminuria
 eGFR 30 mL/min/1.73m2 >30 mL/min/1.73m2 CCr 60 ml/min 45 to 60 
mL/min/1.73m2
30 to <90 
mL/min/1.73m2
 HbA1c 7.0% to 9.0% 7.0% to 10.5% 6.5% to 12.0% 7.0% to 10.5% 6.5% to 12.0%
 UACR no criteria no criteria no criteria no criteria >300 to 5,000 
mg/g
Primary endpoint 3P-MACE 3P-MACE 3P-MACE; CV 
composite of CV 
death or HHF
3P-MACE renal composite of 
ESRD, SCr 
doubling, renal/CV 
































































Secondary CV endpoint 4P-MACE (composite of 
the primary outcome plus 
hospitalisation for 
unstable angina)
all-cause mortality, CV 
death, composite of death 
from CV causes and HHF
no criteria CV death or 
HHF; CV death
composite of CV 
death and HHF; 
CV death; all-
cause death; CV 
composite of CV 





Secondary/exploratory renal endpoint progressi n to 
macroalbuminuria, SCr 
doubling, initiation of RRT 
or death from renal 
disease
renal composite endpoint: 
40% reduction in eGFR, 
need for RRT, or death 





reduction in eGFR, 
new ESRD, or death 
from CV and/or renal 
causes
renal composite 
of renal death, 
dialysis/ 
transplant, or 
doubling of SCr 
from baseline
renal composite 
endpoint of ESRD, 
SCr doubling, and 
renal death; 
composite 
endpoint of ESRD 
and renal/CV 
death; individual 
components of the 
composite 
endpoints
Median follow-up (years) 3.1 2.4 4.2 ongoing 2.6
Patients with established CVD 99% 65.6% 40.6% 99.9% 50.4%
Baseline renal characteristics
 mean eGFR eGFR: 74.0 ml/min/1.73 
m2 (25.9% < 60 and 
74.1% >60 
ml/min/1.73m2); 
76.5 ml/min/1.73 m2 
(20.1% < 60 and 79.9% 
>60 ml/min/1.73m2)
85.2 ml/min/1.73 m2  
(45% between 60 
and 90 ml/min/1.73 
m2  and 7.0% < 60 
ml/min/1.73 m2)
76.0 ml/min/1.73 
m2 (22% < 60 
and 78% >60 
ml/min/1.73m2)
56.2 ml/min/1.73 
m2 (60% < 60 and 
40% >60 
ml/min/1.73m2)































































 median UACR 78 mg/g 12.3 mg/g 13.1 mg/g ns 927.0 mg/g
 microabuminuria 28.5% 22.6% 23.9% 30.2% 11%
 macroalbuminuria 10.9% 7.6% 6.9% 9.2% 88%
Reference(s) 3,6 4 5,7 10 11,12
510 CCr: creatinine clearance rate; CKD: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular disease; eGFR: estimated 
511 glomerular filtration rate; ESRD: end stage renal disease; HbA1c: glycated haemoglobin; HHF: hospitalisation for heart failure; 3-P 
512 MACE: 3 point major adverse cardiovascular event = CV death, nonfatal MI, or nonfatal stroke; ns: not specified; RRT: renal 
513 replacement therapy; SCr: serum creatinine; SGLT2: sodium glucose linked transporter-2; T2D: type-2 diabetes; UACR: Urine 
514 albumin-to-creatinine ratio.












































































Cardiovascular Endpoint: HR (95% CI; P-value)
3-point MACE 0.86 
(0.74-0.99; P <0.001 for 
noninferiority and P =0.04 
for superiority)
0.86
(0.75-0.97; P <0.001 for 






Renal Endpoint: HR (95% CI; P-value)
















40% eGFR reduction 0.54 
(0.43-0.67; P <0.0001)
ESRD (initiation of dialysis) 0.45 





Dialysis, kidney transplant or death 0.72 
(0.54-0.97; P = NA§)




































































516 †Described as the composite risk of doubling of serum creatinine level accompanied by an estimated glomercular filtration rate (eGFR) 
517 of ≤ 45 ml/min/1.73 m2, initiation of renal replacement therapy, or death from renal disease in the EMPA-REG OUTCOME trial; as the 
518 composite risk of 40% reduction in eGFR, renal replacement therapy, or renal death in the CANVAS Program; as the composite risk 
519 of > 40% decrease in eGFR to < 60 ml/min/1.73 m2, ESRD, or death from renal cause in the DECLARE-TIMI 58 trial; and as the 
520 composite outcome of end-stage kidney disease, doubling of serum creatinine level, or renal or cardiovascular death in the 
521 CREDENCE trial.
522 ‡Described as progression to macroalbuminuria in the EMPA-REG OUTCOME trial; as > 30% increase in albuminuria, change from 
523 either normoalbuminuria to micro-/macroalbuminuria or micro- to macroalbuminuria in the CANVAS Program; and as the composite 
524 risk of normo- to micro- or macroalbuminuria in the DECLARE-TIMI 58 trial.
525 §NA: not applicable since P-values were only reported in CREDENCE for outcomes that were included in the hierarchical-testing 
526 strategy. 
527 SGLT2: sodium-glucose linked transporter-2; CVOTs: cardiovascular outcome trials; HR: hazard ratio; CI: confidence interval; CV: 
528 cardiovascular; ESRD: end stage renal disease; eGRF: estimated glomerular filtration rate; NA: not applicable; NR: not reported.































































529 Box 1. Key renal endpoint and outcome considerations with regard to the 
530 EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58 study 
531 designs
532 a. In EMPA-REG OUTCOME, the “new or worsening nephropathy” component of the 
533 microvascular composite outcome was largely driven by cases of new onset 
534 macroalbuminuria, which accounted for over 85% of events.21 
535 As defined, the new onset macroalbuminuria component could capture small, 
536 transient and/or reversible changes in albuminuria of uncertain clinical significance.21 
537 In fact, there was no difference in albuminuria between the placebo and empagliflozin 
538 arms following discontinuation of study drug, suggesting a haemodynamic effect 
539 rather than a direct effect on the underlying disease process.22 
540 b. In EMPA-REG OUTCOME, there was no significant between-group 
541 differences in the rate of incident albuminuria for patients with 
542 normoalbuminuria at baseline (51.5 and 51.2% with empagliflozin and placebo, 
543 respectively; P =0.25).6 However, overall progression to macroalbuminuria was 
544 reduced by 38% (P <0.001), suggesting a different effect of the SGLT2 inhibitor 
545 on patients with different levels of urinary albumin excretion.6
546 Efficacy claims of “sustained normo- or microalbuminuria in patients with baseline 
547 macroalbuminuria” are difficult to maintain.24 To date, regulatory agencies have not 
548 accepted on-treatment effects on albuminuria as a surrogate for clinical outcomes in 
549 diabetic nephropathy, in part because therapies can have acute and reversible 
550 pharmacologic effects on albuminuria that may differ from their long-term effects on 
551 the irreversible loss of renal function and underlying disease progression.25,26































































552 c. The CANVAS Investigators introduced alternative renal endpoints in their 
553 analyses, i.e. a 40% decline in eGFR and eGFR slope, which might be more 
554 practical in trials of shorter duration.4,27 However, since these endpoints are 
555 less applicable at higher baseline renal function (e.g. as typically the case in 
556 CVOTs) and are limited for drugs that cause an acute reduction in eGFR via 
557 haemodynamically-mediated mechanisms (e.g. as with SGLT2 inhibitors), 
558 effects on these endpoints might not translate into true improvement in renal 
559 outcomes. 
560 For each of these outcomes, substituting the 40% reduction in eGFR component with 
561 doubling of serum creatinine resulted in fewer events but similar canagliflozin 
562 treatment effect estimates.4 The results of the composite endpoints were mainly 
563 driven by sustained 40% reduction in eGFR and doubling of serum creatinine.4 
564 db. In CANVAS, the annual eGFR decline was slower with canagliflozin (slope 
565 difference between groups 1.2mL/min/1.73m2/year; 95% CI: 1.0, 1.4).8 This effect is 
566 similar to that observed with RAAS blockers.  An initial, functional ‘dip’ in eGFR is 
567 associated with long-term nephroprotection and is reversible upon discontinuation of 
568 the drug.40 However, as with EMPA-REG OUTCOME, the programme was not 
569 designed to formally examine renal outcomes, the total number of renal events was 
570 small. The decrease in HR for composite renal outcome was driven primarily by the 
571 surrogate endpoints of renal function rather than patient relevant renal outcomes 
572 namely, ESRD, renal transplantation or renal death. 
573 ec. Post-hoc analyses of data from the CANVAS Program have shown that the 
574 beneficial effects of canagliflozin on CV and renal outcomes were not influenced by 
575 baseline renal function in people with T2DM and a history or high risk of CVD down 































































576 to eGFR levels of 30 mL/min/1.73.m2.18 This finding led to the suggestion that the 
577 use of canagliflozin might be appropriate for patients with eGFR levels that are below 
578 the previously recommended level in view of the potential CV and renal benefits of 
579 therapy.41
580 fd. As with the other CVOTs, despite an impressive HR reduction in the exploratory 
581 composite renal endpoint in DECLARE-TIMI 58, it was driven by the components of 
582 eGFR decrease to < 60 mL/min/1.73.m2 and CV death.7  Of note, the patient relevant 
583 renal endpoints of ESRD, renal death and ESRD or renal death were comparatively 
584 rare events in this study.7,42  
585  































































587 Figure 1. Baseline renal risk in study populations of SGLT2 inhibitor CVOTs 
588 and CREDENCE. Adapted from 11.
589 Figure 2. Composite renal outcome rates and composite renal outcome relative 
590 risk reductions (RRRs) in SGLT2 inhibitor CVOTs and CREDENCE. Adapted 
591 from 43. 
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Empaglilozin: EMPA-REG OUTCOME; Canagliflozin: CANVAS Program, and CREDENCE; Dapagliflozin: DECLARE-TIMI 58.
SGLT2: sodium-glucose linked transporter-2; CVOTs: cardiovascular outcome trials; eGRF: estimated glomerular filtration rate; UACR: urine albumin-to-
creatinine ratio.









































































































RRR = 30% 
(P=0.00001)
RRR = 46% 
(P<0.001)
RRR = 40% 
(P<0.001)
RRR = 47% 
(P<0.001)
Due to the heterogeneity of populations and endpoints, any comparison between studies and SGLT-2 inhibitors should be made with caution.

































































I wonder if you might come up with a more eye-catching title that better 
reflects the key conclusions or key message in your review
SGLT-2 Inhibitor Renal Outcome Modification in Type-2 Diabetes: Evidence 
from Studies in Patients with High or Low Renal Risk 
Reviewer 1
It is however noteworthy that, based on the authors prevalences of 
macroalbuminuria given in Table 1, there were 765, 533, 1184 and 758 
persons in EMPA-REG, CANVAS, DECLARE & VERTIS, for a total of 3240 
persons, quite comparable to the 3873 with macroalbuminuria in 
CREDENCE, although the eGFR was certainly lower in the latter trial.   
Statement added: P18, L408:
“Nevertheless, it is noteworthy that there were 765, 533, 1,184 and 758 
persons with baseline macroalbuminuria in EMPA-REG OUTCOME, CANVAS 
Program, DECLARE-TIMI 58 and VERTIS-CV, respectively, for a total of 3240 
persons, which is comparable to the 3,873 with macroalbuminuria in 
CREDENCE, although the prevalence of macroalbuminuria was lower in the 
CVOTs and the eGFR was certainly lower in CREDENCE. “ 
a reasonable combined analysis of the evidence of renal disease 
progression among persons with macroalbuminuria in the four non-renal 
trials would seem to be a powerful way of addressing the question of 
whether renal protection could be considered a feature of all the SGLT2 
inhibitors, and the authors might comment on whether a meta-analysis of 
all the trials using individual patient-level information might be useful in 
better understanding the issue while we await the results of the large trials 
mentioned in the manuscript
Many thanks for this proposal. Since the heterogeneity among the studies 
is so large, we feel that a meta-analysis would be more informative and 
scientifically correct when the other large prospective studies analysing the 
nephroprotective effects of SGLT-2 inhibitors become available.
Box 1 is unusually long for such a manuscript feature, and the very 
interesting points it contains should be incorporated into the appropriate 
sections of the manuscript.  A replacement box of some three or four 
sentences would be more reasonable.
Box 1 has been amended and the interesting points have now been 
incorporated into the appropriate sections of the manuscript, as suggested 
(see P11, L248 and P12, L258 for EMPA-REG OUTCOME comments and P12, 
L277 and P13, L280 for CANVAS Program comments). Box 1 now contains 
only 4 key statements
Box 1(a) suggests that the lack of difference between placebo and 
empagliflozin following study drug discontinuation suggests “a 
hemodynamic effect rather than a direct effect on the underlying disease 
process,” and a similar point is made in 1(c).  Inasmuch as the mechanism 
of the renal effect of SGLT2i might well be hemodynamic (see for example 
van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, 
This comment has been noted and the BOX 1(a) text revised accordingly – 
see P11 L252:
“It has been postulated that SGLT-2 inhibitors exert a haemodynamic effect 
rather than a direct effect on the underlying disease process, however the 
exact mechanism remains to be elucidated. In the recent randomised, 
double-blind RED trial, the renal haemodynamic effects of an SGLT-2 






























































Emanuel AL, Bozovic A, Danser AHJ, Geurts F, Hoorn EJ, Touw DJ, Larsen EL, 
Poulsen HE, Kramer MHH, Nieuwdorp M, Joles JA, van Raalte DH. The renal 
hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by 
post-glomerular vasodilatation rather than pre-glomerular vasoconstriction 
in metformin-treated patients with type 2 diabetes in the randomized, 
double-blind RED trial. Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30991-
3. doi: 10.1016/j.kint.2019.09.013), it seems to this reviewer spurious to 
argue that an effect not present after drug withdrawal would be in some 
fashion not an important aspect of potential renal protection.
inhibitor were shown to be caused by post-glomerular vasodilatation 
rather than pre-glomerular vasoconstriction in metformin-treated T2D 
patients.”
Similarly for BOX 1(c), the following statement has been deleted – see P13 
L294: 
“… and are limited for drugs that cause an acute reduction in eGFR via 
haemodynamically-mediated mechanisms (e.g. as with SGLT2 inhibitors)..”
The Bold section of Box 1(b) addressing different renal protection in 
patients with different levels of albuminuria is an important point, although 
one likely relevant to any agent protecting persons with diabetes against 
DKD development; similarly, different levels of eGFR may be associated 
with different degrees of protection against DKD, and the authors might 
point out that persons with reduction in eGFR without elevations in urinary 
albumin may or may not show benefit from SGLT2i (and that a 
metaanalysis of the sort mentioned above might be particularly useful in 
providing preliminary answers to this question).
The following sentence has been added – see P12 L269:
“It is also important to note that persons with a reduction in eGFR without 
elevations in urinary albumin may or may not show benefit from SGLT-2 
inhibitor treatment, however further trials will be required to determine 
this.”
Regarding the proposal of a meta-analysis: Since the heterogeneity among 
the studies is so large, we feel that a meta-analysis would be more 
informative and scientifically correct when the other large prospective 
studies analysing the nephroprotective effects of SGLT-2 inhibitors become 
available.
Box 1(d) is, again, an interesting point.  It suggests to this reviewer that 
although “the total number of renal events was small,” a large subset of 
patients in the trials showed changes in renal function, both in eGFR and in 
albuminuria, which could certainly be examined to get a sense of the effect 
of the agents on the potential for overall renal function benefit.
We think that examining the data from the large prospective studies 
analysing the nephroprotective effects of SGLT-2 inhibitors when available 
will be more informative in this context.
Rather than using figure 1 in its present form, it would be of interest to give 
the numbers of persons in the intervention and control groups in each trial 
in each of the eGFR vs albuminuria bins.
Figure 1 has been revised with an updated table. However, stratification by 
eGFR and albuminuria categories have been reported only for DECLARE-
TIMI and in a sub-analysis of CANVAS, which means that this information is 
not transferrable for all trials to the heat map in Figure 1. 
Reviewer 2
My only comment is regarding figure 2 - I worry that, given the  
heterogeneity of populations and endpoints, readers will cross-compare 
The following statement has been added at the bottom of figure 2 to avoid 
confusion:






























































between studies and drugs. Thus, I wonder whether it would be better to 
remove Figure 2 to avoid this confusion.
“Due to the heterogeneity of populations and endpoints, any comparison 
between studies and SGLT-2 inhibitors should be made with caution.”
Reviewer 3
Intro, first sentence.  A slight adjustment to the wording of the opening 
sentence may be warranted. Although new glucose-lowering agents have 
been subject to large outcome trials, some beginning in phase 3, some 
beginning as phase 4, the 2008 guidance published by FDA and cited in 
reference #2 of the present manuscript actually refers to the requirement 
for pre-marketing evaluation of CV risk.  “ Sponsors should perform a meta-
analysis of the important cardiovascular events across phase 2 and phase 3 
controlled clinical trials and explore similarities and/or differences in 
subgroups (e.g., age, sex, race), if possible. “
Many thanks for this proposal. Since the heterogeneity among the studies 
is so large, we feel that a meta-analysis would be more informative and 
scientifically correct when the other large prospective studies analysing the 
nephroprotective effects of SGLT-2 inhibitors become available.
Would it be useful to note that although the CVOTs under consideration in 
this manuscript had MACE as the primary endpoint, the regulators asked 
different questions of the sponsors which affected the renal recruitment 
criteria.
Statement incorporated – P9, L190
While views vary concerning the levels of credibility that should be given to 
secondary endpoints, do the authors consider that such renal endpoints 
from CVOTs can be included as part of the labelling of newer agents?  (cf 
comments on Declare).  
Prospective studies analysing primarily kidney endpoints have a much 
higher value and should be used for labelling of newer agents.
Could differences in the duration of follow-up impact findings (given the 
different parameters to be measured), and if so, how should this be 
factored into the design of future trials?  (eg, P15, L351)
Sentence added- see P17, L393:
“Notably, longer duration of follow-up (e.g., 3 years) in kidney trials may 
be more important for renal outcomes than cardiovascular outcomes.”
P6, L132.  I’m not sure that the ESC guideline has been endorsed by the 
EASD because the ESC guideline is at odds with the ADA/EASD consensus 
regarding first-line metformin in patients with very high CV risk.   (also P15, 
L341, and P16, L368, and P19, L426).
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular 
diseases were developed in collaboration with the EASD.
P7, L156   should read “….were…..no criteria….” Amended
P15, L349,  patients who. Amended
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